New obesity drug shows promise in early trial

NCT ID NCT06313528

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage study tested a new drug called LY3437943 in 85 people with obesity. Participants received either the drug or a placebo, and researchers measured how many calories they ate and how their bodies used energy. The goal was to see if the drug could help control appetite and metabolism under a reduced-calorie diet.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3437943
What this could lead to: If successful, this could point toward a new treatment option for obesity that helps control appetite and energy use.
What could go wrong: This is an early Phase 1 study with only 85 participants, so results may not apply broadly. The drug may not show meaningful benefits or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

AdventHealth Orlando

Orlando, Florida, 32804, United States
Columbia University Irving Medical Center

New York, New York, 10032, United States
Pennington Biomedical Research Center

Baton Rouge, Louisiana, 70808, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.